R. Thota

M. Mohty, B. Shaw, S. Rubinstein, 2016, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Pragmatic precision oncology: the secondary uses of clinical tumor molecular profiling

Jeremy L. Warner, Douglas B. Johnson, Matthew J. Rioth, 2016, J. Am. Medical Informatics Assoc..

APC and TP53 Mutations Predict Cetuximab Sensitivity across Consensus Molecular Subtypes

Lance T. Pflieger, T. Yeatman, M. Schell, 2021, Cancers.

Trametinib in the treatment of melanoma

J. Sosman, Douglas B. Johnson, R. Thota, 2015, Expert opinion on biological therapy.

Preclinical Rationale for the Phase III Trials in Metastatic Pancreatic Cancer: Is Wishful Thinking Clouding Successful Drug Development for Pancreatic Cancer?

J. Berlin, A. Maitra, R. Thota, 2017, Pancreas.

Characterization of the tumor mutation burden in hepatobiliary tumors.

L. Nadauld, T. Rhodes, T. Barker, 2019, Journal of Clinical Oncology.

Clinicopathologic factors associated with lymph node retrieval in resectable colon cancer: A veterans' affairs central cancer registry (VACCR) database analysis

I. Aldoss, T. Tashi, A. Ganti, 2011, Journal of surgical oncology.

An integrative gene expression signature analysis identifies CMS4 KRAS-mutated colorectal cancers sensitive to combined MEK and SRC targeted therapy

Lance T. Pflieger, T. Yeatman, M. Schell, 2022, BMC Cancer.

Ras Pathway Activation and MEKi Resistance Scores Predict the Efficiency of MEKi and SRCi Combination to Induce Apoptosis in Colorectal Cancer

Lance T. Pflieger, T. Yeatman, Mingli Yang, 2022, Cancers.

Moving Beyond the Momentum: Innovative Approaches to Clinical Trial Implementation

P. Philip, E. Chen, S. Krishnamurthi, 2021, JCO oncology practice.

Cetuximab in Patients with Breast Cancer, Non-Small Cell Lung Cancer, and Ovarian Cancer Without KRAS, NRAS, or BRAF Mutations: Results from the Targeted Agent and Profiling Utilization Registry (TAPUR) Study

R. Schilsky, C. Calfa, E. Garrett-Mayer, 2020, Targeted Oncology.

A Phase II Study of Ganetespib as Second-line or Third-line Therapy for Metastatic Pancreatic Cancer

J. Berlin, G. Ayers, E. Chan, 2017, American journal of clinical oncology.

Differential methylation of G-protein coupled receptor signaling genes in gastrointestinal neuroendocrine tumors

L. Cannon-Albright, K. Curtin, D. Neklason, 2021, Scientific Reports.

American Society of Clinical Oncology Road to Recovery Report: Learning From the COVID-19 Experience to Improve Clinical Research and Cancer Care.

Jonathan M Marron, Laura A. Levit, R. Schilsky, 2020, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Apparent heparin resistance in a patient with infective endocarditis secondary to elevated factor VIII levels

A. Ganti, S. Subbiah, R. Thota, 2012, Journal of Thrombosis and Thrombolysis.

Barriers and Facilitators to Telemedicine: Can You Hear Me Now?

R. Thota, K. Lam, A. López, 2021, American Society of Clinical Oncology educational book. American Society of Clinical Oncology. Annual Meeting.

A phase II study of ganetespib (G) as second- or third-line therapy for metastatic pancreatic cancer (MPC).

J. Berlin, G. Ayers, E. Chan, 2014 .

Could the PD-1 Pathway Be a Potential Target for Treating Small Intestinal Adenocarcinoma?

J. Berlin, C. Shi, D. Cardin, 2016, American journal of clinical pathology.

Palbociclib (P) in patients (pts) with head and neck cancer (HNC) with CDKN2A loss or mutation: Results from the Targeted Agent and Profiling Utilization Registry (TAPUR) study.

R. Schilsky, C. Calfa, F. Worden, 2021 .

Genitourinary small cell carcinoma: Analysis of clinical and treatment factors associated with survival among patients in the Veterans Affairs Health System.

I. Aldoss, T. Tashi, S. Subbiah, 2010 .

Systemic amyloidosis masquerading as iron deficiency anemia

T. Tashi, S. Subbiah, W. Gonsalves, 2012, Indian Journal of Gastroenterology.

Trametinib in the treatment of melanoma

J. Sosman, Douglas B. Johnson, R. Thota, 2015, Expert opinion on biological therapy.

Pembrolizumab in Patients With Tumors With High Tumor Mutational Burden: Results From the Targeted Agent and Profiling Utilization Registry Study

R. Schilsky, Rui Li, A. Alva, 2023, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Palbociclib (P) in patients (pts) with non-small cell lung cancer (NSCLC) with CDKN2A alterations: Results from the Targeted Agent and Profiling Utilization Registry (TAPUR) Study.

R. Schilsky, C. Calfa, E. Garrett-Mayer, 2019, Journal of Clinical Oncology.